Background Clostridium difficile infection is a serious diarrheal illness associated with
substantial morbidity and mortality. Patients generally have a response to oral vancomycin or …

Background Current therapies for recurrent Clostridioides difficile infection do not address
the disrupted microbiome, which supports C. difficile spore germination into toxin-producing …

Background. Clostridium difficile infection (CDI) is a common complication of antibiotic therapy
that is treated with antibiotics, contributing to ongoing disruption of the colonic microbiota …

… In a study by Louie et al [4], mean Bacteroides counts in feces were similar at the beginning
and end of fidaxomicin treatment (day 10), but use of vancomycin resulted in counts that …

Clostridioides difficile infection (CDI) is classified as an urgent health threat by the Centers
for Disease Control and Prevention (CDC), and affects nearly 500,000 Americans annually. …

The microflora-sparing properties of fidaxomicin were examined during the conduct of a
randomized clinical trial comparing vancomycin 125 mg 4 times per day versus fidaxomicin 200 …

Handwashing is the single most important procedure in the prevention of nosocomial infections
and yet it remains the most violated où all infection control procedures. With a sequential …

Two recently completed phase 3 trials (003 and 004) showed fidaxomicin to be noninferior
to vancomycin for curing Clostridium difficile infection (CDI) and superior for reducing CDI …

Background. Treatment guidelines recommend stopping all implicated antibiotics at the
onset of Clostridium difficile infection (CDI), but many individuals have persistent or new …

Background . Current antibiotic therapies for Clostridium difficile–associated diarrhea have
limitations, including progression to severe disease, recurrent C. difficile–associated diarrhea…